Among other changes in recommendations, the AAP and the CDC have removed their previous minimum interval between administering a tetanus or diphtheria vaccine and the Tdap. Medscape Medical News
No Comments »
Filed under: General Health News
If a child is at imminent risk for exposure, with planned travel to certain countries, the AAP recommends that the IPV doses be administered at minimum ages and intervals. Medscape Medical News
No Comments »
Filed under: General Health News
(MedPage Today) — The American Academy of Pediatrics (AAP) has updated some of its vaccine guidance to harmonize recommendations with those of the Advisory Committee on Immunization Practices.
No Comments »
Filed under: General Health News
With the advent of personalised medicine, gains in cancer survival over the long term could be improved by running smaller, faster trials with less stringent evidence criteria, a researcher told the 2011 European Multidisciplinary Cancer Congress.
No Comments »
Filed under: Pharmacy News
Pacira Pharmaceuticals, Inc. today announced that the company’s lead investigational product for postsurgical pain management, EXPAREL, was highlighted in the “Hot Topics in Plastic Surgery” panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo.
No Comments »
Filed under: Pharmacy News
A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress.
No Comments »
Filed under: Pharmacy News
ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.
No Comments »
Filed under: Pharmacy News
Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.
No Comments »
Filed under: Pharmacy News
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
No Comments »
Filed under: Pharmacy News
Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.
No Comments »
Filed under: Pharmacy News
